Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade B $38.51 1.40% 0.53
PTLA closed up 1.4 percent on Wednesday, March 22, 2017, on 4 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Mar 17 Slingshot Bullish Bullish Swing Setup -2.36%
Mar 16 New 52 Week High Bullish -4.20%
Mar 15 New 52 Week High Bullish -5.75%
Mar 13 1,2,3 Pullback Bullish Bullish Swing Setup 0.34%
Mar 13 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.34%
Mar 10 NR7 Range Contraction 0.73%
Mar 10 NR7-2 Range Contraction 0.73%
Mar 10 Narrow Range Bar Range Contraction 0.73%
Mar 10 1,2,3 Pullback Bullish Bullish Swing Setup 0.73%
Mar 10 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.73%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company’s products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.27
52 Week Low 15.68
Average Volume 23,016,161
200-Day Moving Average 24.4097
50-Day Moving Average 31.5748
20-Day Moving Average 37.775
10-Day Moving Average 39.161
Average True Range 1.6684
ADX 31.57
+DI 22.91
-DI: 19.35
Chandelier Exit (Long, 3 ATRs) 36.2648
Chandelier Exit (Short, 3 ATRs) 34.5052
Upper Bollinger Band 42.2116
Lower Bollinger Band 33.3384
Percent B (%b) 0.58
Bandwidth 0.234896